Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Meeting the needs of CML patients in resource-poor countries

Hemant Malhotra, Jerald Radich, Pat Garcia-Gonzalez

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 433–442.

https://doi.org/10.1182/hematology.2019000050

Published: 2019

Journal Articles

Molecular monitoring in CML: how deep? How often? How should it influence therapy?

Naranie Shanmuganathan, Timothy P. Hughes

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 168–176.

https://doi.org/10.1182/asheducation-2018.1.168

Published: 2018

Journal Articles

The argument for using imatinib in CML

Simone Claudiani, Jane F. Apperley

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 161–167.

https://doi.org/10.1182/asheducation-2018.1.161

Published: 2018

Journal Articles

The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors

Fabio Efficace, Laura Cannella

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 170–179.

https://doi.org/10.1182/asheducation-2016.1.170

Published: 2016

Journal Articles

Molecular monitoring in chronic myeloid leukemia—how low can you go?

Susan Branford

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 156–163.

https://doi.org/10.1182/asheducation-2016.1.156

Published: 2016

Journal Articles

Chronic myeloid leukemia: sequencing of TKI therapies

Jorge Cortes, Hagop Kantarjian

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 164–169.

https://doi.org/10.1182/asheducation-2016.1.164

Published: 2016

Journal Articles

Is there a best TKI for chronic phase CML?

Richard A. Larson

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 250–256.

https://doi.org/10.1182/asheducation-2015.1.250

Published: 2015

Journal Articles

Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

David T. Yeung, Michael J. Mauro

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 240–243.

https://doi.org/10.1182/asheducation-2014.1.240

Published: 2014

Journal Articles

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?

Kendra Sweet, Vivian Oehler

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 184–188.

https://doi.org/10.1182/asheducation-2013.1.184

Published: 2013

Journal Articles

Which TKI? An embarrassment of riches for chronic myeloid leukemia patients

Timothy Hughes, Deborah White

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 168–175.

https://doi.org/10.1182/asheducation-2013.1.168

Published: 2013

Journal Articles

Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond

Wesam Ahmed, Richard A. Van Etten

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 189–200.

https://doi.org/10.1182/asheducation-2013.1.189

Published: 2013

Journal Articles

Monitoring after successful therapy for chronic myeloid leukemia

Susan Branford

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 105–110.

https://doi.org/10.1182/asheducation.V2012.1.105.3798223

Published: 2012

Journal Articles

Monitoring disease response in chronic-phase chronic myeloid leukemia: the age of molecular assays?

David T. Yeung, Susan Branford

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 111–114.

https://doi.org/10.1182/asheducation.V2012.1.111.3806846

Published: 2012

Journal Articles

Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia

David Marin

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 115–121.

https://doi.org/10.1182/asheducation.V2012.1.115.3798209

Published: 2012

Journal Articles

Is going for cure in chronic myeloid leukemia possible and justifiable?

François-Xavier Mahon

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 122–128.

https://doi.org/10.1182/asheducation.V2012.1.122.3798214

Published: 2012

Journal Articles

Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia: Approach to Patients with Treatment-Naive or Refractory Chronic-Phase Disease

Catherine C. Smith, Neil P. Shah

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 121–127.

https://doi.org/10.1182/asheducation-2011.1.121

Published: 2011

Journal Articles

Tyrosine Kinase Inhibitor Use in Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Anemia

Stephen P. Hunger

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 361–365.

https://doi.org/10.1182/asheducation-2011.1.361

Published: 2011

Journal Articles

Angiogenesis: A Target in Solid Tumors, Also in Leukemia?

Thomas Schmidt, Peter Carmeliet

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 1–8.

https://doi.org/10.1182/asheducation-2011.1.1

Published: 2011

Journal Articles

Educational Session: Managing Chronic Myeloid Leukemia as a Chronic Disease

Andreas Hochhaus

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 128–135.

https://doi.org/10.1182/asheducation-2011.1.128

Published: 2011

Journal Articles

Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure?

Junia V. Melo, David M. Ross

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 136–142.

https://doi.org/10.1182/asheducation-2011.1.136

Published: 2011

NARROW

Meeting the needs of CML patients in resource-poor countries

Molecular monitoring in CML: how deep? How often? How should it influence therapy?

The argument for using imatinib in CML

The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors

Molecular monitoring in chronic myeloid leukemia—how low can you go?

Chronic myeloid leukemia: sequencing of TKI therapies

Is there a best TKI for chronic phase CML?

Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?

Which TKI? An embarrassment of riches for chronic myeloid leukemia patients

Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond

Monitoring after successful therapy for chronic myeloid leukemia

Monitoring disease response in chronic-phase chronic myeloid leukemia: the age of molecular assays?

Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia

Is going for cure in chronic myeloid leukemia possible and justifiable?

Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia: Approach to Patients with Treatment-Naive or Refractory Chronic-Phase Disease

Tyrosine Kinase Inhibitor Use in Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Anemia

Angiogenesis: A Target in Solid Tumors, Also in Leukemia?

Educational Session: Managing Chronic Myeloid Leukemia as a Chronic Disease

Minimal Residual Disease and Discontinuation of Therapy in Chronic Myeloid Leukemia: Can We Aim at a Cure?

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only